Alto Neuroscience (ANRO) vs Kardigan (KARD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kardigan is the larger company by market cap ($1.08 billion vs $1.02 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANRO | KARD |
|---|---|---|
| Share price | $25.37 | $11.54 |
| Market cap | $1.02B | $1.08B |
| 1-day change | -4.30% | -7.83% |
| YTD return | +42.53% | — |
| 1-year return | +91.47% | — |
| EPS (TTM) | $-2.32 | $-6.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-63.24M | — |
| 52-week high | $37.48 | $27.00 |
| 52-week low | $12.51 | $11.49 |
| Distance from 52-week high | -32.31% | -57.26% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +52.42% | +255.29% |
| Average volume | 614.92K | 625.83K |
| Shares outstanding | 40.11M | 93.60M |
| Employees | 68 | 241 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alto Neuroscience
ANRO stock →Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 68 employees
About Kardigan
KARD stock →Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 241 employees
ANRO vs KARD FAQ
Which is bigger, Alto Neuroscience or Kardigan?
Kardigan (KARD) is larger, with a market capitalization of $1.08B compared with $1.02B for Alto Neuroscience (ANRO).
Are Alto Neuroscience and Kardigan in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.